The blockade of immune checkpoints in cancer immunotherapy

Pardoll, Drew M.·2012·Nature Reviews Cancer
DOI 10.1038/nrc3239

Cited by (1,121)

Items 201–300 of 1,121

  1. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
    Bertrand, Anne, Kostine, Marie, Barnetche, Thomas, Truchetet, Marie-Elise, Schaeverbeke, Thierry · 2015 · BMC Medicine
  2. New horizons in tumor microenvironment biology: challenges and opportunities
    Chen, Fei, Zhuang, Xueqian, Lin, Liangyu, Yu, Pengfei, Wang, Ying, Shi, Yufang, Hu, Guohong, Sun, Yu · 2015 · BMC Medicine
  3. Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy
    Yuanzeng Min, Kyle C. Roche, Shaomin Tian, Michael Joseph Eblan, Karen P. McKinnon, Joseph Michael Caster, Shengjie Chai, Laura E. Herring, Longzhen Zhang, Tian Zhang et al. · 2017 · Nature Nanotechnology
  4. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
    Antonio Passaro, Maise Al Bakir, Emily G. Hamilton, Maximilian Diehn, Fabrice André, Sinchita Roy‐Chowdhuri, Giannis Mountzios, Ignacio Ivan Wistuba, Charles Swanton, Solange Peters · 2024 · Cell
  5. Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination
    Rong Yang, Jun Xu, Ligeng Xu, Xiaoqi Sun, Qian Chen, Yuhuan Zhao, Rui Peng, Zhuang Liu · 2018 · ACS Nano
  6. Neoantigen vaccine: an emerging tumor immunotherapy
    Peng Miao, Yongzhen Mo, Yian Wang, Pan Wu, Yijie Zhang, Fang Xiong, Can Jie Guo, Steven Wu, Yong Li, Xiaoling Li et al. · 2019 · Molecular Cancer
  7. Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
    Liza B. John, Christel Devaud, Connie P.M. Duong, Carmen S. M. Yong, Paul A. Beavis, Nicole M. Haynes, Melvyn T. Chow, Mark John Smyth, Michael H. Kershaw, Phillip Kevin Darcy · 2013 · Clinical Cancer Research
  8. TIP: A Web Server for Resolving Tumor Immunophenotype Profiling
    Liwen Xu, Chunyu Deng, Bo Pang, Xinxin Zhang, Wei Liu, Gaoming Liao, Huating Yuan, Cheng Peng, Feng Li, Zhilin Long et al. · 2018 · Cancer Research
  9. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
    Jonathan Wade Goldman, Mikhail Vladimirovich Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro V. Trukhin, Galina Statsenko, Maximilian Johannes Hochmair, Mustafa Özgüroğlu, Jun Ho Ji et al. · 2020 · The Lancet Oncology
  10. Near-Infrared-Triggered Photodynamic Therapy with Multitasking Upconversion Nanoparticles in Combination with Checkpoint Blockade for Immunotherapy of Colorectal Cancer
    Jun Xu, Ligeng Xu, Chenya Wang, Rong Yang, Qi Zhuang, Xiao Han, Ziliang Dong, Wenwen Zhu, Rui Peng, Zhuang Liu · 2017 · ACS Nano
  11. Chemodynamic Therapy via Fenton and Fenton‐Like Nanomaterials: Strategies and Recent Advances
    Chenyang Jia, Yuxin Guo, Fu‐Gen Wu · 2021 · Small
  12. Cancer immunotherapy: Pros, cons and beyond
    Shuzhen Tan, Dongpei Li, Xiao Ming Zhu · 2020 · Biomedicine & Pharmacotherapy
  13. CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
    Patrick Alexander Ott, Frank Stephen Hodi, Caroline Robert · 2013 · Clinical Cancer Research
  14. Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells
    De Simone, Marco, Arrigoni, Alberto, Rossetti, Grazisa, Gruarin, Paola, Ranzani, Valeria, Politano, Claudia, Bonnal, Raoul J.P., Provasi, Elena, Sarnicola, Maria Lucia, Panzeri, Ilaria et al. · 2016 · Immunity
  15. An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer
    Encouse B. Golden, Sandra Demaria, Peter B. Schiff, Abraham Chachoua, Silvia Chiara Formenti · 2013 · Cancer Immunology Research
  16. The mathematics of cancer: integrating quantitative models
    Philipp M. Altrock, Lin L. Liu, Franziska Michor · 2015 · Nature reviews. Cancer
  17. PDL1 Regulation by p53 via miR-34
    Cortez, Maria Angelica, Ivan, Cristina, Valdecanas, David, Wang, Xiaohong, Peltier, Heidi J., Ye, Yuping, Araujo, Luiz, Carbone, David P., Shilo, Konstantin, Giri, Dipak K et al. · 2016 · JNCI: Journal of the National Cancer Institute
  18. Tumor Immunotherapy Directed at PD-1
    Antoni Ribas · 2012 · New England Journal of Medicine
  19. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
    Kim, KiBem, Skora, Andrew D., Li, Zhaobo, Liu, Qiang, Tam, Ada J., Blosser, Richard L., Diaz, Luis A., Papadopoulos, Nickolas, Kinzler, Kenneth W., Vogelstein, Bert et al. · 2014 · Proceedings of the National Academy of Sciences
  20. Non-small-cell lung cancer
    Lizza E.L. Hendriks, Jordi Remón, Corinne Faivre Finn, Marina Chiara Garassino, John Victor Heymach, Keith M. Kerr, Daniel S.W. Tan, Giulia Veronesi, Martin Reck · 2024 · Nature Reviews Disease Primers
  21. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
    Nan Chen, Wenfeng Fang, Jianhua Zhan, Shaodong Hong, Yanna Tang, Shiyang Kang, Yaxiong Zhang, Xiaobo He, Ting Zhou, Tao Qin et al. · 2015 · Journal of Thoracic Oncology
  22. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
    Philippe A. Armand, Margaret Ann Shipp, Vincent Ribrag, Jean‐Marie Michot, Pier Luigi Zinzani, John G. Kuruvilla, Ellen Snyder, Alejandro Daniel Ricart, Arun Balakumaran, Shelonitda Rose et al. · 2016 · Journal of Clinical Oncology
  23. Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
    Huang, Yuhui, Goel, Shom, Duda, Dan G., Fukumura, Dai, Jain, Rakesh K. · 2013 · Cancer Research
  24. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy
    Arlauckas, Sean P., Garris, Christopher S., Kohler, Rainer H., Kitaoka, Maya, Cuccarese, Michael F., Yang, Katherine S., Miller, Miles A., Carlson, Jonathan C., Freeman, Gordon J., Anthony, Robert M. et al. · 2017 · Science Translational Medicine
  25. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
    Daud, Adil I., Wolchok, Jedd D., Robert, Caroline, Hwu, Wen-Jen, Weber, Jeffrey S., Ribas, Antoni, Hodi, F. Stephen, Joshua, Anthony M., Kefford, Richard, Hersey, Peter et al. · 2016 · Journal of Clinical Oncology
  26. Nanoscale Metal–Organic Framework Overcomes Hypoxia for Photodynamic Therapy Primed Cancer Immunotherapy
    Guangxu Lan, Kaiyuan Ni, Ziwan Xu, Samuel S. Veroneau, Yang Song, Wenbin Lin · 2018 · Journal of the American Chemical Society
  27. Nanoparticle‐Enhanced Radiotherapy to Trigger Robust Cancer Immunotherapy
    Qian Chen, Jiawen Chen, Zhijuan Yang, Jun Xu, Ligeng Xu, Chao Liang, Xiao Han, Zhuang Liu · 2019 · Advanced Materials
  28. Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes
    Deborah B. Doroshow, Miguel F. Sanmamed, Katherine Hastings, Katerina A. Politi, David L. Rimm, Lieping Chen, Ignacio Melero, Kurt Alex Schalper, Roy S. Herbst · 2019 · Clinical Cancer Research
  29. Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection
    Hudson, William H., Gensheimer, Julia, Hashimoto, Masao, Wieland, Andreas, Valanparambil, Rajesh M., Li, Peng, Lin, Jian-Xin, Konieczny, Bogumila T., Im, Se Jin, Freeman, Gordon J. et al. · 2019 · Immunity
  30. TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment
    Ya Han, Yuting Wang, Xin Dong, Dongqing Sun, Zhaoyang Liu, Jiali Yue, Haiyun Wang, Taiwen Li, Chenfei Wang · 2022 · Nucleic Acids Research
  31. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
    Hua, Camille, Boussemart, Lise, Mateus, Christine, Routier, Emilie, Boutros, Céline, Cazenave, Hugo, Viollet, Roxane, Thomas, Marina, Roy, Séverine, Benannoune, Naima et al. · 2016 · JAMA Dermatology
  32. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes
    Sachet Ashok Shukla, Michael S. Rooney, Mohini Rajasagi, Grace Tiao, Philip M. Dixon, Michael S. Lawrence, Jonathan D. Stevens, William J. Lane, Jamie L. DellaGatta, Scott Steelman et al. · 2015 · Nature Biotechnology
  33. Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
    Coelho, Matthew A., de Carné Trécesson, Sophie, Rana, Sareena, Zecchin, Davide, Moore, Christopher, Molina-Arcas, Miriam, East, Philip, Spencer-Dene, Bradley, Nye, Emma, Barnouin, Karin et al. · 2017 · Immunity
  34. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
    Andrew B. Sharabi, Christopher J. Nirschl, Christina M. Kochel, Thomas R. Nirschl, Brian J. Francica, Esteban Velarde, Theodore L. DeWeese, Charles G. Drake · 2014 · Cancer Immunology Research
  35. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
    Kim, J.M., Chen, D.S. · 2016 · Annals of Oncology
  36. Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
    Daniel S. Chen, Bryan A. Irving, Frank Stephen Hodi · 2012 · Clinical Cancer Research
  37. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
    Sonja Kleffel, Christian Posch, Steven R. Barthel, Hansgeorg Mueller, Christoph Schlapbach, Emmanuella Guenova, Christopher P. Elco, Nayoung Lee, Vikram R. Juneja, Qian Zhan et al. · 2015 · Cell
  38. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer
    Koichi Azuma, Keiichi Ota, Akihiko Kawahara, Satoshi Hattori, Eiji Iwama, Takeshi Harada, Koichiro Matsumoto, Koichi Takayama, Shinzo Takamori, M. Kage et al. · 2014 · Annals of Oncology
  39. Cancer immunotherapies targeting the PD-1 signaling pathway
    Yoshiko Iwai, Junzo Hamanishi, Kenji Chamoto, Tasuku Honjo · 2017 · Journal of Biomedical Science
  40. PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer
    Cécile Badoual, Stéphane Hans, Nathalie Merillon, Cordélia Van Ryswick, Patrice Ravel, Nadine Benhamouda, Émeline Levionnois, Mevyn Nizard, Ali Si‐Mohamed, Nicolas Besnier et al. · 2012 · Cancer Research
  41. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
    Ri‐Yao Yang, Linlin Sun, Ching-Fei Li, Yu-Han Wang, Jun Yao, Hui Li, Meisi Yan, Wei‐Chao Chang, Jung-Mao Hsu, Jong‐Ho Cha et al. · 2021 · Nature Communications
  42. Evolving synergistic combinations of targeted immunotherapies to combat cancer
    Ignacio Melero, David M. Berman, Maria Angela Aznar, Alan J. Korman, José Luis Perez‐Gracia, John B.A.G. Haanen · 2015 · Nature reviews. Cancer
  43. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
    Sylvia Adams, Sherene Loi, Deborah Toppmeyer, David W. Cescon, Michelino De Laurentiis, Rita Nanda, Eric P. Winer, Hirofumi Mukai, Kenji Tamura, Anne Caroline Armstrong et al. · 2018 · Annals of Oncology
  44. CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients
    Djenidi, Fayçal, Adam, Julien, Goubar, Aïcha, Durgeau, Aurélie, Meurice, Guillaume, de Montpréville, Vincent, Validire, Pierre, Besse, Benjamin, Mami-Chouaib, Fathia · 2015 · The Journal of Immunology
  45. Adaptive Immune Resistance: How Cancer Protects from Immune Attack
    Antoni Ribas · 2015 · Cancer Discovery
  46. Advances in targeted therapies for hepatocellular carcinoma in the genomic era
    Josep Maria Llovet, Augusto Villanueva, Anja Lachenmayer, Richard S. Finn · 2015 · Nature Reviews Clinical Oncology
  47. Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer
    K.G.K. Deepak, Rahul Kumar Vempati, Ganji Purnachandra Nagaraju, Venkata Ramesh Dasari, Siddavaram Nagini, D.N. Rao, Rama Rao Malla · 2020 · Pharmacological Research
  48. The interaction of anticancer therapies with tumor-associated macrophages
    Alberto Mantovani, Paola Allavena · 2015 · The Journal of Experimental Medicine
  49. Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity
    Elise Alspach, Danielle M. Lussier, Robert D. Schreiber · 2018 · Cold Spring Harbor Perspectives in Biology
  50. Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response
    Kim, Oh Youn, Park, Hyun Taek, Dinh, Nhung Thi Hong, Choi, Seng Jin, Lee, Jaewook, Kim, Ji Hyun, Lee, Seung-Woo, Gho, Yong Song · 2017 · Nature Communications
  51. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness
    Tuoqi Wu, Yun Ji, E. Ashley Moseman, Haifeng C. Xu, Monica Manglani, Martha Kirby, Stacie M. Anderson, Robin Handon, Elizabeth Kenyon, Abdel G. Elkahloun et al. · 2016 · Science Immunology
  52. Metabolic barriers to cancer immunotherapy
    Kristin DePeaux, Greg M. Delgoffe · 2021 · Nature reviews. Immunology
  53. Melanoma
    Dirk Schadendorf, David E. Fisher, Claus Garbe, Jeffrey E. Gershenwald, Jean‐Jacques Grob, Allan C. Halpern, Meenhard Herlyn, Michael Armando Marchetti, Grant A. McArthur, Antoni Ribas et al. · 2015 · Nature Reviews Disease Primers
  54. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy
    Shalapour, Shabnam, Font-Burgada, Joan, Di Caro, Giuseppe, Zhong, Zhenyu, Sanchez-Lopez, Elsa, Dhar, Debanjan, Willimsky, Gerald, Ammirante, Massimo, Strasner, Amy, Hansel, Donna E. et al. · 2015 · Nature
  55. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
    Chia‐Wei Li, Seung‐Oe Lim, Ezra M. Chung, Yongsoo Kim, Andrew H Park, Jun Yao, Jong‐Ho Cha, Weiya Xia, Li-Chuan Chan, Tae‐Wan Kim et al. · 2018 · Cancer Cell
  56. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
    Ricklefs, Franz L., Alayo, Quazim, Krenzlin, Harald, Mahmoud, Ahmad B., Speranza, Maria C., Nakashima, Hiroshi, Hayes, Josie L., Lee, Kyungheon, Balaj, Leonora, Passaro, Carmela et al. · 2018 · Science Advances
  57. Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy
    Chen, Xiaoying, Firulyova, Maria, Manis, Melissa, Herz, Jasmin, Smirnov, Igor, Aladyeva, Ekaterina, Wang, Chanung, Bao, Xin, Finn, Mary Beth, Hu, Hao et al. · 2023 · Nature
  58. Tumor neoantigens: building a framework for personalized cancer immunotherapy
    Matthew M. Gubin, Maxim N. Artyomov, Elaine R. Mardis, Robert D. Schreiber · 2015 · Journal of Clinical Investigation
  59. Emerging blood–brain-barrier-crossing nanotechnology for brain cancer theranostics
    Wei Tang, Wenpei Fan, Joseph Lau, Liming Deng, Zheyu Shen, Xiaoyuan Shawn Chen · 2019 · Chemical Society Reviews
  60. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
    Florent Petitprez, Maxime Meylan, Aurélien de Reyniès, Catherine Sautès‐Fridman, Wolf H. Fridman · 2020 · Frontiers in Immunology
  61. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
    Grosser, Rachel, Cherkassky, Leonid, Chintala, Navin, Adusumilli, Prasad S. · 2019 · Cancer Cell
  62. Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape
    Malte Mohme, Sabine Riethdorf, Klaus Pantel · 2016 · Nature Reviews Clinical Oncology
  63. Low-dose X-ray radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks enhances checkpoint blockade immunotherapy
    Kuangda Lu, Chunbai He, Nining Guo, Christina Chan, Kaiyuan Ni, Guangxu Lan, Haidong Tang, Charles A. Pelizzari, Yang‐Xin Fu, Michael T. Spiotto et al. · 2018 · Nature Biomedical Engineering
  64. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
    Romano, Emanuela, Kusio-Kobialka, Monika, Foukas, Periklis G., Baumgaertner, Petra, Meyer, Christiane, Ballabeni, Pierluigi, Michielin, Olivier, Weide, Benjamin, Romero, Pedro, Speiser, Daniel E. · 2015 · Proceedings of the National Academy of Sciences
  65. Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
    Hoos, Axel · 2016 · Nature Reviews Drug Discovery
  66. Immunological mechanisms of the antitumor effects of supplemental oxygenation
    Hatfield, Stephen M., Kjaergaard, Jorgen, Lukashev, Dmitriy, Schreiber, Taylor H., Belikoff, Bryan, Abbott, Robert, Sethumadhavan, Shalini, Philbrook, Phaethon, Ko, Kami, Cannici, Ryan et al. · 2015 · Science Translational Medicine
  67. Drug resistance and new therapies in colorectal cancer
    Jeught, Kevin Van der, Xu, Han-Chen, Li, Yu-Jing, Lu, Xiong-Bin, Ji, Guang · 2018 · World Journal of Gastroenterology
  68. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
    Yearley, Jennifer H., Gibson, Christopher, Yu, Ni, Moon, Christina, Murphy, Erin, Juco, Jonathan, Lunceford, Jared, Cheng, Jonathan, Chow, Laura Q.M., Seiwert, Tanguy Y. et al. · 2017 · Clinical Cancer Research
  69. <i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
    Jenkins, Russell W., Aref, Amir R., Lizotte, Patrick H., Ivanova, Elena, Stinson, Susanna, Zhou, Chensheng W., Bowden, Michaela, Deng, Jiehui, Liu, Hongye, Miao, Diana et al. · 2018 · Cancer Discovery
  70. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
    Armida D’Incecco, Mariacarla Andreozzi, Vienna Ludovini, Elisa Rossi, Alessandra Capodanno, Lorenza Maria Landi, Carmelo Tibaldi, Gabriele Minuti, Jessica Salvini, Erika Coppi et al. · 2014 · British Journal of Cancer
  71. Going viral with cancer immunotherapy
    Brian Dennis Lichty, Caroline J. Breitbach, David F. Stojdl, John Cameron Bell · 2014 · Nature reviews. Cancer
  72. Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
    Weide, Benjamin, Martens, Alexander, Hassel, Jessica C., Berking, Carola, Postow, Michael A., Bisschop, Kees, Simeone, Ester, Mangana, Johanna, Schilling, Bastian, Di Giacomo, Anna Maria et al. · 2016 · Clinical Cancer Research
  73. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities
    Xiufang Xu, Miaofeng Zhang, Faying Xu, Shaojie Jiang · 2020 · Molecular Cancer
  74. Cancer Stem Cells: The Architects of the Tumor Ecosystem
    Briana C. Prager, Qi Xie, Shideng Bao, Jeremy N. Rich · 2019 · Cell stem cell
  75. Targetable genetic features of primary testicular and primary central nervous system lymphomas
    Bjoern Chapuy, Margaretha G.M. Roemer, Chip Stewart, Yuxiang Tan, Ryan Abo, Liye Zhang, Andrew J Dunford, David M. Meredith, Aaron R. Thorner, Ekaterina S. Jordanova et al. · 2015 · Blood
  76. Microbiome and cancer
    Cullin, Nyssa, Azevedo Antunes, Camila, Straussman, Ravid, Stein-Thoeringer, Christoph K., Elinav, Eran · 2021 · Cancer Cell
  77. Resistance to PD1/PDL1 checkpoint inhibition
    Jake S. O’Donnell, Georgina Venetia Long, Richard A. Scolyer, Michele W.L. Teng, Mark John Smyth · 2016 · Cancer Treatment Reviews
  78. Clinical management of breast cancer heterogeneity
    Dimitrios Zardavas, Alexandre Irrthum, Charles Swanton, Martine J Piccart · 2015 · Nature Reviews Clinical Oncology
  79. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
    Paul C. Tumeh, Matthew David Hellmann, Omid Hamid, Katy K. Tsai, Kimberly Leticia Loo, Matthew A. Gubens, Michael D. Rosenblum, Christina L. Harview, Janis Marie Taube, Nathan R. Handley et al. · 2017 · Cancer Immunology Research
  80. Exosomes and tumor-mediated immune suppression
    Theresa L. Whiteside · 2016 · Journal of Clinical Investigation
  81. Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside
    Triantafyllos Stylianopoulos, Lance L. Munn, Rakesh K. Jain · 2018 · Trends in cancer
  82. Immune checkpoint blockade in infectious diseases
    Michelle Wykes, Sharon R. Lewin · 2017 · Nature reviews. Immunology
  83. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
    Garassino, Marina Chiara, Cho, Byoung-Chul, Kim, Joo-Hang, Mazières, Julien, Vansteenkiste, Johan, Lena, Hervé, Corral Jaime, Jesus, Gray, Jhanelle E, Powderly, John, Chouaid, Christos et al. · 2018 · The Lancet Oncology
  84. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
    Igor J. Puzanov, Mohammed M. Milhem, David R. Minor, Omid Hamid, Li Ai, Lisa Chen, Michael A. Chastain, Kevin S. Gorski, Abraham Anderson, Jeffrey Chou et al. · 2016 · Journal of Clinical Oncology
  85. Improving immune–vascular crosstalk for cancer immunotherapy
    Huang, Yuhui, Kim, Betty Y. S., Chan, Charles K., Hahn, Stephen M., Weissman, Irving L., Jiang, Wen · 2018 · Nature Reviews Immunology
  86. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade
    Shen, Jianfeng, Ju, Zhenlin, Zhao, Wei, Wang, Lulu, Peng, Yang, Ge, Zhongqi, Nagel, Zachary D., Zou, Jun, Wang, Chen, Kapoor, Prabodh et al. · 2018 · Nature Medicine
  87. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
    Meyer, Christiane, Cagnon, Laurène, Costa-Nunes, Carla M., Baumgaertner, Petra, Montandon, Nicole, Leyvraz, Loredana, Michielin, Olivier, Romano, Emanuela, Speiser, Daniel E. · 2014 · Cancer Immunology Immunotherapy
  88. Apigenin in cancer therapy: anti-cancer effects and mechanisms of action
    Xiaohui Yan, Miao Qi, Pengfei Li, Yihong Zhan, Huanjie Shao · 2017 · Cell & Bioscience
  89. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
    Cheng Xu, Yu‐Pei Chen, Xiao-Jing Du, Jin-Qi Liu, Cheng-Long Huang, Lei Chen, Guan‐Qun Zhou, Wen‐Fei Li, Yan‐Ping Mao, Chiun Hsu et al. · 2018 · BMJ
  90. Next generation of immune checkpoint inhibitors and beyond
    Julian Andres Marin-Acevedo, ErinMarie O. Kimbrough, Yanyan Lou · 2021 · Journal of Hematology & Oncology
  91. Regulatory circuits of T cell function in cancer
    Daniel E. Speiser, Ping‐Chih Ho, Grégory Verdeil · 2016 · Nature reviews. Immunology
  92. DNA mismatch repair in cancer
    Marina Baretti, Dung Thi Le · 2018 · Pharmacology & Therapeutics
  93. Near‐Infrared‐Light‐Activatable Nanomaterial‐Mediated Phototheranostic Nanomedicines: An Emerging Paradigm for Cancer Treatment
    Raviraj Vankayala, Kuo Chu Hwang · 2018 · Advanced Materials
  94. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications
    Simona Sivori, Paola Vacca, Genny Del Zotto, Enrico Munari, Maria Cristina Mingari, Lorenzo Moretta · 2019 · Cellular and Molecular Immunology
  95. Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis
    Takahiro Tsujikawa, Sushil Kumar, Rohan N. Borkar, Vahid Azimi, Guillaume Thibault, Young Hwan Chang, Ariel I. Balter, Rie Kawashima, Gina H. Choe, David Sauer et al. · 2017 · Cell Reports
  96. Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature
    Baran, Burcin, Mert Ozupek, Nazli, Yerli Tetik, Nihal, Acar, Emine, Bekcioglu, Omer, Baskin, Yasemin · 2018 · Gastroenterology Research
  97. Immune-mediated antitumor effect by type 2 diabetes drug, metformin
    Shingo Eikawa, Mikako Nishida, Shusaku Mizukami, Chihiro Yamazaki, Eiichi Nakayama, Heiichiro Udono · 2015 · Proceedings of the National Academy of Sciences
  98. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
    Eléonora De Martin, Jean‐Marie Michot, Barbara Papouin, Stéphane Champiat, Christine Mateus, Olivier Lambotte, Bruno Roche, Térésa Antonini, Audrey Coilly, Salim Laghouati et al. · 2018 · Journal of Hepatology
  99. TIGIT as an emerging immune checkpoint
    Harjunpää, H, Guillerey, C · 2020 · Clinical and Experimental Immunology
  100. Epigenetic therapy in immune-oncology
    Peter A. Jones, Hitoshi Ohtani, Ankur Chakravarthy, Daniel Diniz De Carvalho · 2019 · Nature reviews. Cancer